Amino Asylum Alternatives: Vetting a Successor After the June 2025 FDA Raid | Artemis Labs
Amino Asylum Alternatives: Vetting a Successor After the June 2025 Raid
Published August 21, 2026 · Artemis Labs
Amino Asylum alternatives — Amino Asylum stopped processing orders when FDA agents raided its warehouse facility in June 2025; the site went dark overnight and pending orders were frozen. A successor should be chosen on verification, not price: third-party COAs pairing HPLC purity with MS identity, primary-literature citations, published policies, and no administration supplies anywhere in the catalog.
Key findings
- The raid was a first. The June 2025 action against Amino Asylum was the first physical FDA raid on a major research-peptide vendor — a different enforcement tier from the 100+ warning letters sent to peptide sellers since September 2025.
- Continuity risk lands on the buyer. When Amino Asylum went dark, payment processing was terminated and pending orders froze in place; the cost of a vendor’s compliance posture is paid, in part, by its research customers.
- The guilty pleas you may have read about belong to a different vendor. The Kawa and Stechkober pleas come from the Paradigm Peptides prosecution; the verified Amino Asylum record covers the raid and its consequences only.
What happened to Amino Asylum in June 2025
The record is short and dated. On or about June 18, 2025, FDA agents raided Amino Asylum’s warehouse facility. The website went dark overnight. Payment processing was terminated. Pending orders were frozen. At the time, third-party traffic tools placed the site in the range of 400,000 monthly visitors — an estimate, not an audited figure. Two vendor-industry accounts of the event are linked in the References below.
What the raid meant for buyers — orders, funds, purchase records — is reconstructed date by date in our companion piece, the Amino Asylum raid timeline. This page takes up the question that follows it: what should replace Amino Asylum in a research program, and on what evidence.
A raid is not a warning letter
FDA enforcement in the research-peptide market runs on a ladder, and it matters where a vendor’s event sits on it. A warning letter — like the four issued to GLP-1-class sellers on December 10, 2024, or the seven-site batch dated March 31, 2026 — is correspondence. It documents the agency’s findings, sets a 15-working-day response window, and the company keeps operating while it responds. More than 100 such letters have gone to peptide and research-chemical sellers since September 2025.
A physical raid is a different instrument. Agents arrive, evidence is collected, and operations stop at once — which is why Amino Asylum’s buyers experienced the event as a site that worked one evening and did not exist the next morning. Above the raid tier sits criminal prosecution, and the market now has a fully adjudicated example in the Paradigm Peptides case — a separate company with a separate court record. The two cases are frequently blended in secondary coverage, and should not be.
Business continuity is a selection criterion researchers routinely skip
Vendor comparisons in this market usually weigh three things: catalog, price, and a purity number. Almost nobody weighs the fourth: whether the vendor will exist next quarter, and what happens to open orders and purchase records if it does not. Amino Asylum’s June 2025 shutdown answered that question for its buyers overnight, with no wind-down notice.
Continuity risk is not random — it correlates with compliance posture. A vendor whose public materials read as intended human use carries enforcement exposure, and FDA’s 2024–2026 letters name the patterns the agency reads that way: therapeutic-outcome claims, administration supplies offered in the same cart, coded drug names. A researcher does not need to adjudicate any of that to act on it. If a storefront shows those patterns, its continuity risk is being carried, in part, by every open order on its books.
Verification-first criteria for an Amino Asylum successor
The criteria below are the same ones our supplier-evaluation framework applies to any vendor, Artemis Labs included:
- A COA with every order, pairing purity with identity. HPLC establishes how pure the material is; mass spectrometry establishes what it is. Identity is the test that catches mislabeled material — our guide to reading a Certificate of Analysis shows where each appears on the document.
- Primary-literature citations on product pages. A vendor describing compounds by mechanism and citation — not outcome language — is documenting, not promising.
- Nothing in the catalog that reads as intended human use. No administration supplies, no dosing content — the exact patterns FDA’s March 2026 letter batch cites.
- Published, findable policies. Shipping, refunds, privacy, and research-use terms, all reachable before checkout.
- Honest handling of unfavorable findings. A vendor that surfaces counter-evidence against its own catalog is showing you how it will behave when something matters.
How Artemis Labs answers each criterion
Measured against that list, here is what Artemis Labs can state factually. Every order ships with a third-party Certificate of Analysis covering HPLC purity and MS identity verification. Roughly 500 PubMed and DOI citations run across the catalog, with a References section on every product page. When the literature cuts against a compound we carry, it goes on the page — the 2025 Sun finding on Tβ4 is disclosed on the relevant product page. We sell no administration supplies and publish no dosing or administration content anywhere. Shipping, refund, privacy, and research-use terms are published and reachable before checkout; the refund policy sets out what we stand behind and what we do not. Everything in the Artemis Labs catalog is supplied for laboratory research use only.
Two things Artemis Labs does not yet claim, because they are not yet live: a public COA lot-lookup portal and published per-lot chromatograms. A COA ships with every order in the meantime. We would rather list the gap than imply the feature.
Frequently asked questions
Is Amino Asylum still operating?
The verified record ends at the June 2025 raid: the site went dark overnight, payment processing was terminated, and pending orders were frozen. The sources reviewed for this article document nothing reliable about a return to operations, so any site now trading on the Amino Asylum name deserves independent verification before an order.
Did Amino Asylum’s operators plead guilty to federal charges?
No plea by anyone connected to Amino Asylum appears in the sources verified for this article. The pleas widely attached to this story — Matthew Kawa and Jennifer Stechkober, December 2025 — belong to the separate Paradigm Peptides case, a search-summary blend this article deliberately keeps apart.
What should a replacement supplier show before it earns an order?
Third-party COAs pairing HPLC purity with MS identity, dense primary-literature citations, no administration supplies or dosing content, published policies, and a record of disclosing unfavorable findings. Price and catalog breadth come after all five, not before.
Why does a raid change vendor selection more than a warning letter does?
Because a warning letter leaves the vendor operating through a 15-working-day response window, while a raid stops operations immediately — Amino Asylum’s buyers lost order access overnight. Continuity risk of that severity is worth weighing in every supplier decision, before the event, not after it. Our running record of who has left the market is on the 2025–2026 peptide vendor closures hub.
References
- PS Peptides — “What Happened to Amino Asylum Peptides”
- The Peptide Catalog — “Amino Asylum Shut Down: Alternatives”
- CBS News — peptides seller prison sentence for unapproved drugs (the separate Paradigm Peptides case)
